Skip to content

Jenna M Traynor

Gunderson Personality Disorders Research Institute, McLean Hospital, Belmont, Massachusetts (Traynor, Choi-Kain); Faculty of Medicine, Harvard Medical School, Boston (Traynor, Choi-Kain); Langone Center for Psychedelic Medicine, Department of Psychiatry, New York University Grossman School of Medicine, New York (Roberts, Ross); Department of Psychology, Ryerson University, Toronto (Zeifman); Centre for Psychedelic Research, Imperial College London, London (Zeifman).

1 paper in the library · 14 citations · publishing 2022

Papers

MDMA-Assisted Psychotherapy for Borderline Personality Disorder.

Focus (American Psychiatric Publishing) October 1, 2022 Jenna M Traynor, Daniel E Roberts, Stephen Ross et al. 14 citations

Borderline personality disorder is a complex psychiatric condition with limited and often ineffective treatment options, high variability in patient response, and frequent dropout from therapy. This review considers the potential of MDMA-assisted psychotherapy (MDMA-AP) as a new or complementary treatment. Based on MDMA-AP's promise in treating overlapping disorders like posttraumatic stress disorder, the authors propose initial treatment targets and hypothesized mechanisms of change grounded in prior literature and theory. They also outline considerations for designing clinical trials to investigate the safety, feasibility, and preliminary effects of MDMA-AP for borderline personality disorder.

DOI: 10.1176/appi.focus.20220056 Full text Borderline personality disorder Drug treatment/psychopharmacology MDMA-Assisted Psychotherapy Clinical trials +4